In a 40‑year‑old female with axillary nodules that repeatedly drain purulent material and scar, which concomitant disease is most commonly associated?

Hidradenitis Suppurativa with Inflammatory Bowel Disease

You should expect to find inflammatory bowel disease, specifically Crohn's disease, which occurs in approximately 2% of patients with hidradenitis suppurativa and carries a 3-fold increased risk compared to the general population 1, 2.

Clinical Presentation Analysis

The clinical picture described—axillary nodules with purulent drainage and scarring in a 40-year-old woman—is pathognomonic for hidradenitis suppurativa (HS). This chronic inflammatory condition characteristically affects intertriginous areas (axillae, groin, inframammary folds) with recurrent painful nodules, abscesses, and eventual scar formation 3.

Most Important Comorbidity: Inflammatory Bowel Disease

Crohn's Disease Association

• Prevalence: 2% among HS patients versus 0.6% in non-HS patients 2
• Risk magnitude: 3-fold increased odds (aOR 3.05; 95% CI 2.87-3.25) 2
• Shared pathophysiology: Both conditions involve suppuration, granulomatous inflammation, and fistula/sinus tract formation 2
• Common cytokine pathways: TNF, IL-1, and IL-17 drive both diseases, explaining response to shared biologic therapies 1

Ulcerative Colitis Association

• Prevalence: 1% among HS patients 1
• Risk magnitude: 1.8 times increased odds compared to controls 1

Algorithmic Screening Approach

For this 40-year-old woman with confirmed HS, screen for:

1. Gastrointestinal symptoms (highest priority given 3-fold Crohn's risk):

   • Chronic diarrhea, abdominal pain, weight loss, rectal bleeding
   • Consider fecal calprotectin if symptomatic
   • Gastroenterology referral for colonoscopy if positive

2. Metabolic syndrome components (affects up to 50% of HS patients):

   • Diabetes mellitus screening (25% prevalence, 2-3× increased odds) 1
   • Lipid panel and blood pressure monitoring

3. Mental health screening (depression prevalence up to 30%):

   • Depression and anxiety screening tools
   • Suicide risk assessment (2.4× increased risk; crude incidence 0.3 per 1000 person-years) 1

4. Cardiovascular risk (1.5× increased MACE risk):

   • Baseline cardiovascular assessment given chronic systemic inflammation 2

Key Clinical Pitfalls

• Don't dismiss GI symptoms as unrelated: The shared inflammatory pathways mean HS and IBD frequently coexist, not coincidentally
• Age and sex matter: This patient fits the highest-risk demographic (women aged 18-39 have the highest HS prevalence) 1
• Comorbidity burden exceeds psoriasis: HS carries greater overall comorbidity burden than psoriasis, affecting mortality risk 1

Evidence Strength

The recommendations are based on 2024 and 2022 guidelines from the US and Canadian HS Foundations 1, 2, representing the most current evidence-based screening recommendations specifically designed to improve long-term health outcomes and quality of life in HS patients.